Caribou Biosciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Caribou Biosciences, Inc. (NASDAQ: CRBU) is a clinical-stage biopharmaceutical company leveraging proprietary CRISPR-based genome-editing technologies to develop allogeneic, off-the-shelf CAR-T cell therapies for hematologic malignancies and autoimmune diseases. Founded in 2011 and headquartered in Berkeley, California, the company employs its patented Cas9 and Cas12a chRDNA platforms for precise multiplex editing, including TRAC knockout and CAR insertion, PD-1 knockout for checkpoint disruption, and B2M-HLA-E fusion for immune cloaking; its lead product candidate, vispa-cel (formerly CB-010), is an anti-CD19 CAR-T therapy in the ANTLER Phase 1 trial for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL), featuring FDA Regenerative Medicine Advanced Therapy, Fast Track, and Orphan Drug designations, while CB-011 is an anti-BCMA CAR-T therapy in the CaMMouflage Phase 1 trial for relapsed or refractory multiple myeloma (r/r MM) with Fast Track and Orphan Drug status. Caribou operates primarily in the United States with international ambitions through scalable manufacturing for broad patient access to rapid, off-the-shelf treatments targeting oncology and autoimmune indications. In April 2025, the company announced a strategic pipeline prioritization, discontinuing earlier-stage programs like CB-012 and CB-020, reducing its workforce by 32%, and implementing cost cuts to extend its cash runway into the second half of 2027, while maintaining focus on CB-010 and CB-011; recent milestones include positive Phase 1 data disclosures in November 2025 for both programs, with vispa-cel demonstrating efficacy in second-line large B cell lymphoma and CB-011 establishing a 450 million CAR-T cell recommended dose for expansion in r/r MM, alongside ongoing FDA discussions for potential pivotal trials.
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
Three Best Genomics Stocks for Your Portfolio in 2026
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update